Hangzhou Leap Chem Co., Ltd. is one of the most professional manufacturers and suppliers of sunitinib malate丨cas 341031-54-7 in China. Welcome to wholesale bulk high quality chemical products at competitive price from our factory. If you have any enquiry about custom service, please feel free to email us.
Specifications
| Description | Orange powder |
| Purity | 98% min |
| Water | 0.5% max |
| Melting point | 189～191°C |
| Residue on ignition | 0.2% max |
| Ordinary impurities | |
| Single impurity | 1.0% max |
| Total impurities | 2.0% max |
Transport Information
|
Parameter |
Specification |
|
UN Number |
|
|
Class |
|
|
Packing Group |
|
|
H.S. Code |
2933990099306 |
|
Stability & Reactivity |
The product is chemically stable under standard ambient conditions. |
|
Storage |
Keep container tightly closed. Store in a cool and shaded area. Keep under inert gas. Recommended storage temperature -25 - -15 °C. |
|
Condition to Avoid |
|
|
Package |
Manufacturing Information
|
Parameter |
Specification |
|
Capacity |
100kg/year |
|
Frequency |
|
|
Main Export Countries |
|
|
Capacity/Batch |
|
|
Experience |
Production since 2015 |
|
Stock |
Applications
1. Anticancer Therapy
Sunitinib malate is an oral targeted cancer therapy used primarily for:
Renal cell carcinoma (RCC)
Gastrointestinal stromal tumors (GIST)
Pancreatic neuroendocrine tumors (pNET)
It inhibits tumor growth and angiogenesis by blocking multiple receptor tyrosine kinases.
2. Multi-Targeted Tyrosine Kinase Inhibitor
Targets various RTKs including:
Vascular endothelial growth factor receptors (VEGFR 1, 2, 3)
Platelet-derived growth factor receptors (PDGFR α and β)
c-KIT
FLT3
RET
Inhibition of these receptors disrupts signaling pathways crucial for tumor angiogenesis, proliferation, and metastasis.
3. Antiangiogenic Agent
By inhibiting VEGFR and PDGFR, sunitinib suppresses blood vessel formation, starving tumors of oxygen and nutrients.
Benefits
✅ Effective in Multiple Cancer Types
FDA-approved for several cancers, demonstrating improved progression-free survival and overall survival in many patients.
✅ Oral Administration
Convenient oral dosing allows outpatient treatment and improved quality of life.
✅ Multi-Targeted Action
Broad spectrum of kinase inhibition limits tumor resistance and targets tumor microenvironment.
✅ Well-Studied Pharmacokinetics
Predictable absorption, metabolism (primarily CYP3A4), and elimination facilitate dose optimization.
Conclusion
Sunitinib malate (CAS 341031-54-7) is a versatile and potent oral tyrosine kinase inhibitor widely used in the treatment of renal cell carcinoma, gastrointestinal stromal tumors, and pancreatic neuroendocrine tumors. Its ability to simultaneously target multiple signaling pathways essential for tumor growth and angiogenesis makes it a cornerstone in targeted cancer therapies. With manageable side effects and oral convenience, sunitinib malate significantly advances patient care in oncology.
